Citadel Advisors
BTAI icon

Citadel Advisors’s BioXcel Therapeutics BTAI Stock Holding History

Citadel Advisors’s Portfolio BTAI Stock Details BTAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-3,713
Closed -$22.2K – 14525
2024
Q4 		$22.2K Buy
3,713
+1,982
+115% +$16.6K ﹤0.01% 13113
2024
Q3 		$16.9K Sell
1,731
-2,382
-58% -$32K ﹤0.01% 12909
2024
Q2 		$84.2K Sell
4,113
-743
-15% -$24.9K ﹤0.01% 11151
2024
Q1 		$219K Sell
4,856
-700
-13% -$33.4K ﹤0.01% 10130
2023
Q4 		$262K Sell
5,556
-1,132
-17% -$62.9K ﹤0.01% 9426
2023
Q3 		$271K Buy
6,688
+1,282
+24% +$130K ﹤0.01% 9347
2023
Q2 		$576K Buy
5,406
+4,525
+514% +$1.51M ﹤0.01% 7629
2023
Q1 		$263K Sell
881
-557
-39% -$238K ﹤0.01% 9649
2022
Q4 		$494K Buy
1,438
+188
+15% +$45.5K ﹤0.01% 8266
2022
Q3 		$236K Sell
1,250
-1,381
-52% -$321K ﹤0.01% 10069
2022
Q2 		$556K Buy
2,631
+350
+15% +$73.6K ﹤0.01% 8413
2022
Q1 		$763K Sell
2,281
-1,769
-44% -$513K ﹤0.01% 8351
2021
Q4 		$1.32M Buy
4,050
+131
+3% +$56.2K ﹤0.01% 7220
2021
Q3 		$1.9M Sell
3,919
-1,169
-23% -$514K ﹤0.01% 6489
2021
Q2 		$2.37M Buy
5,088
+1,319
+35% +$719K ﹤0.01% 6182
2021
Q1 		$2.6M Buy
3,769
+744
+25% +$599K ﹤0.01% 5775
2020
Q4 		$2.24M Buy
3,025
+1,262
+72% +$983K ﹤0.01% 5124
2020
Q3 		$1.22M Sell
1,763
-912
-34% -$685K ﹤0.01% 5664
2020
Q2 		$2.27M Buy
2,675
+1,681
+169% +$1.1M ﹤0.01% 4343
2020
Q1 		$355K Buy
+994
New +$357K ﹤0.01% 7030

Other funds holding BTAI

Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
OCM
Oaktree Capital Management Los Angeles, California $7.21B AUM 45.97% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OFA
Oaktree Fund Advisors Los Angles, California $57.8M AUM 67.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Citadel Advisors's BTAI Position: Q2 2026 in Review

Citadel Advisors opened a new position in BioXcel Therapeutics (BTAI) in Q2 2026: 149,220 shares worth $210K. The stake represents ﹤0.01% of the portfolio and ranks #11950 among its holdings. This is a return to the name: Citadel Advisors previously reported a position in BTAI as recently as Q2 2025.

Citadel Advisors first reported a position in BTAI in Q2 2020 and has held it in 18 quarters since. The position peaked at $37.6M in Q4 2020. 47 funds tracked by Wall St. Rank hold BTAI as of Q2 2026.

  • Citadel Advisors held 149,220 shares of BioXcel Therapeutics worth $210K as of Q2 2026.
  • BioXcel Therapeutics was a new Citadel Advisors position in Q2 2026.
  • BioXcel Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #11950 holding.
  • Citadel Advisors first reported a position in BioXcel Therapeutics in Q2 2020 and has held it in 18 quarters since.
  • Citadel Advisors's BioXcel Therapeutics position peaked at $37.6M in Q4 2020.
  • 47 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.